Company’s 36-month beta value is 0.25.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for MRVI is 107.06M, and currently, short sellers hold a 12.77% ratio of that floaft. The average trading volume of MRVI on June 11, 2025 was 2.43M shares.
MRVI) stock’s latest price update
The stock price of Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) has jumped by 5.79 compared to previous close of 2.16. Despite this, the company has seen a gain of 3.39% in its stock price over the last five trading days. accessnewswire.com reported 2025-06-10 that NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. (“Maravai” or “the Company”) (NASDAQ:MRVI). Investors who purchased Maravai securities prior to August 7, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/MRVI.
MRVI’s Market Performance
Maravai LifeSciences Holdings Inc (MRVI) has experienced a 3.39% rise in stock performance for the past week, with a 7.78% rise in the past month, and a -12.45% drop in the past quarter. The volatility ratio for the week is 6.99%, and the volatility levels for the past 30 days are at 5.20% for MRVI. The simple moving average for the past 20 days is 3.21% for MRVI’s stock, with a -53.35% simple moving average for the past 200 days.
Analysts’ Opinion of MRVI
Many brokerage firms have already submitted their reports for MRVI stocks, with Robert W. Baird repeating the rating for MRVI by listing it as a “Neutral.” The predicted price for MRVI in the upcoming period, according to Robert W. Baird is $3 based on the research report published on February 26, 2025 of the current year 2025.
Goldman gave a rating of “Sell” to MRVI, setting the target price at $4.25 in the report published on December 05th of the previous year.
MRVI Trading at 10.15% from the 50-Day Moving Average
After a stumble in the market that brought MRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.22% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRVI starting from ORESHACK KURT, who sale 25,000 shares at the price of $5.03 back on Jan 31 ’25. After this action, ORESHACK KURT now owns 167,618 shares of Maravai LifeSciences Holdings Inc, valued at $125,750 using the latest closing price.
ORESHACK KURT, the Officer of Maravai LifeSciences Holdings Inc, proposed sale 25,000 shares at $5.03 during a trade that took place back on Jan 31 ’25, which means that ORESHACK KURT is holding shares at $125,750 based on the most recent closing price.
Stock Fundamentals for MRVI
Current profitability levels for the company are sitting at:
- -1.1 for the present operating margin
- 0.37 for the gross margin
The net margin for Maravai LifeSciences Holdings Inc stands at -0.67. The total capital return value is set at -0.3. Equity return is now at value -45.75, with -13.53 for asset returns.
Based on Maravai LifeSciences Holdings Inc (MRVI), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at 0.18. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -8.85.
Currently, EBITDA for the company is -156.92 million with net debt to EBITDA at 1.19. When we switch over and look at the enterprise to sales, we see a ratio of 0.35. The receivables turnover for the company is 8.49for trailing twelve months and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.96.
Conclusion
In a nutshell, Maravai LifeSciences Holdings Inc (MRVI) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
